But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Novartis will not pursue Kymriah’s use in second-line lymphoma; but have Breyanzi and Yescarta proved enough to be filed in this setting?
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.